

Serial No.: 09/709,613  
Filed: November 10, 2000  
RESPONSE TO RESTRICTION REQUIREMENT

Examination of claims 1-11 on the merits is earnestly solicited.

Respectfully submitted,



Patrea L. Pabst  
Reg. No. 31,284

Date: July 29, 2002  
HOLLAND & KNIGHT LLP  
One Atlantic Center, Suite 2000  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3400  
(404) 817-8473  
(404) 817-8588 (Fax)

#### CERTIFICATE OF FACSIMILE TRANSMITTAL

I hereby certify that this correspondence and any document referred to as being included therein is being facsimile transmitted to the Patent and Trademark Office on July 29, 2002.

  
Jean Hicks

**APPENDIX: Marked up Copy of Amended Claims**

1. A method for inducing an immune response against transformed, infected or diseased tissue comprising  
contacting the blood of a patient in need thereof with an effective amount of a molecule binding to soluble cytokine receptor molecules, wherein the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoietin, G-CSF, M-CSF and SCF, wherein binding of the molecule prevents the soluble cytokine receptor from binding to the cytokine, until the transformed, infected, or diseased tissue is reduced in amount.
2. The method of claim 1 wherein the tissue is a solid tumor.
3. The method of claim 1 wherein the disease is a viral or parasitic disease causing immunosuppression.
4. The method of claim 1 wherein the molecule is an antibody to the soluble cytokine receptor.
5. The method of claim 1 further comprising treating the tissue with an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation.
6. The method of claim 1 further comprising selectively removing soluble cytokine receptor molecules.
7. The method of claim 1 wherein the soluble cytokine receptor molecules are selected from the group consisting of soluble tissue necrosis factor receptor-1 ("sTNFR-1") and soluble tissue necrosis factor receptor-2 ("sTNFR-2").
8. The method of claim 7 wherein the cytokine receptor molecules are removed by binding to the cytokine or to an antibody or antibody fragment immunoreactive with the cytokine receptor molecules.
9. The method of claim 8 wherein the cytokine or antibody or antibody fragments are immobilized in a filter or column through which the patient's blood or plasma is circulated prior to being returned to the patient.
10. The method of claim 4 wherein the antibody is humanized.

Serial No.: 09/709,043

Filed: November 10, 2000

## RESPONSE TO RESTRICTION REQUIREMENT

11. (amended) [A composition for inducing an immune response against transformed, infected or diseased tissue] The method of claim 1 comprising contacting the blood or components thereof with molecules binding to soluble cytokine receptor molecules, wherein the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoietin, G-CSF, M-CSF and SCF, wherein binding of the molecule prevents the soluble cytokine receptor from binding to the cytokine, in an amount effective to reduce the amount of transformed, infected, or diseased tissue, wherein the molecules are in a pharmaceutically acceptable, endotoxin free carrier or immobilized in a sterile endotoxin free extracorporeal device.